Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1997-11-13
2000-06-06
MacMillan, Keith D.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514401, A61K 31415
Patent
active
060719427
ABSTRACT:
Methods for obtaining beneficial stable levels of circulating histamine are disclosed for use in methods for enhancing natural killer cell cytotoxicity and for elevating histamine levels in individuals in need thereof. In such methods, a beneficial level of circulating histamine is attained and an agent whose ability to enhance natural killer cell cytotoxicity is augmented by histamine is administered. Alternatively, stable beneficial levels of circulating histamine can be attained in subjects receiving chemotherapy or antiviral treatment. The invention may also be employed in treatments combining histamine, agents which enhance natural killer cell cytotoxicity, and chemotherapeutic agents. Optimization of the delivery of histamine and substances which induce the release of endogenous histamine are also disclosed.
REFERENCES:
patent: 5348739 (1994-09-01), Hellstrand
patent: 5478211 (1995-12-01), Dominiak et al.
"Rote Liste 1996", Editio Cantor, 1996, Aulendorf, Germany Abstract XP002092726, Abstract of "Histadestal".
The Influence of Intraperitoneal Injections of Histamine on Tumour Growth in Fibrosarcoma-Bearing Mice, Burtin, et al., Cancer Letters, 12(3):195-201, Jan. 1981.
Successful Tumour Immunotherapy with Cimetidine in Mice, Osband, et al., The Lancet, No. 8221, 1:636-638, Mar. 21, 1981.
Factors Regulating Availability of Histamine at Tissue Receptors Ganellin and Parsons, eds., Pharmacology of Histamine Receptors, Beaven, Chapter Three, pp. 103-145, .COPYRGT. 1982.
Hydroxyl radical scavengers inhibit lymphocyte mitogenesis Novogrodsky, et al., Proc. Natl. Acad. Sci. USA, 79:1171-1174, Feb. 1982.
Suppression of Natural Killing in Vitro by Monocytes and Polymorphonuclear Leukocytes, Seaman, et al., The Journal of Clinical Investigation, 69:876-888, Apr. 1982.
The Differential Effects of Human Leukocytic Pyrogen/Lymphocyte-Activating Factor, T Cell Growth Factor, and Interferon on Human Natural Killer Activity, Dempsey, et al., The Journal of Immunology, May 17, 1982.
Tumor-Enhancing Effects of Cimetidine, Barna, et al., Oncology, 40:43-45, 1983.
Decreased blood histamine levels in patients with solid malignant tumors Burtin, et al., Br. J. Cancer, 47:367-372, 1983.
Combination of Cimetidine with other Drugs for Treatment of Cancer, Thornes, et al., New England Journal of Medicine 308:591-592, Mar. 10, 1983.
The Effect of Histamine, Antihistamines, and a Mast Cell Stabilizer on the Growth of Cloudman Melanoma Cells in DBA/2 Mice Nordlund, et al., Journal of Investivative Dermatology, 81(1):28-31, Jul. 1983.
The Influence of Histamine on Immune and Inflammatory Responses, Beer, et al., Advances in Immunology, 35:209-268, 1984.
Hydroxyl radical scavengers inhibit human natural killer cell activity, Suthanthiran, et al., Nature 307:276-278, Jan. 1984.
Enhancement by serotonin of intra-tumour penetration of spleen cells, Lespinatas, et al., Br. J. Cancer, 50:545-547, Apr. 5, 1984.
Compared Mechanisms of Tumor Cytolysis by Human Natural Killer Cells and Activated Polymorphonuclear Leukocytes, Abrams, et al., The Journal of Immunology 132(6):3192-3196, Jun. 1984.
Down-Regulation of Human Natural Killer Activity Against Tumors by the Neutrophil Myeloperoxidase System and Hydrogen Peroxide, El-Hag, et al., The Journal of Immunology 133(6):3291-3297, Dec. 1984.
Effect of Ascorbic Acid on Human Natural Killer Cells, Huwyler, et al., Immunology Letters, 10:173-176, 1985.
The Role of Natural Killer Cells in the Control of Tumor Growth and Metastasis, Nabil Hanna, Biochimica et Biophysica Acta, 780:213-226, 1985.
Induction of Interferon-.gamma. Production by Human Natural Killer Cells Stimulated by Hydrogen Peroxide, Munakata, et al., The Journal of Immunology, 134(4):2449-2455, Apr. 1985.
Natural Killer Cell-Mediated Lysis Involves an Hydroxyl Radical-Dependent Step, Duwe, et al., The Journal of Immunology, 134(4):2637-2644, Apr. 1985.
Cytotoxicity by human adherent cells: oxygen-dependent and -independent cytotoxic reactions by different cell populations, Kessel, et al., Immunology, 58:291-296, 1986.
Histamine augments interleukin-2 production and the activation of cytotoxic T lymphocytes, Droege, et al., Chemical Abstracts, 104:No. 146898m, p. 146891, 1986.
Histamine Augments Interleukin-2 Production and the Activation of Cytotoxic T Lymphocytes, Droge, et al., Immunopharmacology, 11:1-6, 1986.
Histamine Inhibits Interferon-.gamma. Production via Suppression of Interleukin 2 Synthesis, Dohlsten, et al., Cellular Immunology, 101:493-501, 1986.
Histamine-Induced Suppressor Factor Inhibition of NK Cells: Reversal with Interferon and Interleukin 2, Nair, et al., The Journal of Immunology, 136(7):2456-2462, Apr. 1, 1986.
Hydeoperoxide Metabolism in Cyanobacteria, Tel-Or, et al., Archives of Biochemistry and Biophysics, 246(1):396-402, Apr. 1986.
Histamine H.sub.2 -Receptor-Mediated Regulation of Human Natural Killer Cell Activity, Hellstrand, et al., The Journal of Immunology, 137(2):656-660, Jul. 15, 1986.
Biogenic Amines in the Regulation of Human Natural Killer Cell Cytotoxicity (Thesis), Hellstrand, Medi Press, Goteborg, Sweden, 1987.
Differential Effects of Histamine Receptor Antagonists on Human Natural Killer Cell Activity, Hellstrand, et al., Int. Archs Allergy appl. Immunology, 84:247-255, 1987.
Selective, Histamine-Mediated Immunosuppression in Laryngeal Cancer, Richtsmeier, et al., Ann Otol Rhinol Laryngol, 96(5):569-572, 1987.
Thyroid Hermone Regulates TRH Biosynthesis in the Paraventricular Necleus of the Rat Hypothalamus Segerson, et al., Science, 238:78-80.
A Progress Report on the Treatment of 157 Patients With Advanced Cancer Using Lymphokine-Activated Killer Cells and Interleukin-2 or High-Dose Interleukin-2 Alone Rosenberg, et al., N. Eng. Journal of Medicine, 316(15):889-897, Apr. 9, 1987.
Clinical Improvement in Advanced Cancer Disease After Treatment Combining Histamine and H2-Antihistaminics (Ranitidine or Cimetidine), Burtin, et al., Eur. Journal of Cancer Clin. Oncol., 24(2):161-167, 1988 (Accepted Jun. 1987).
Identification of Cellular Mechanisms Operational In Vivo During the Regression of Established Pulomonary Metastases by the Systemic Administration of High-Dose Recombinant Interleukin 2 Mule, et al., Journal of Immunology, 139(1):285-294, Jul. 1987.
Role of Serotonin in the Regulation of Human Natural Killer Cell Cytotoxicity, Hellstrand, et al., The Journal of Immunology, 139(2):869-875, Aug. 1, 1987.
The IL-2 Receptor .beta. Chain (p70): Role in Mediating Signals for LAK, NK, and Proliferative Activities, Siegel, et al., Science, vol. 238, Oct. 2, 1987.
Chondrocyte Antioxidant Defenses: The Roles of Catalase and Gluthathione Peroxidase in Protection Against H.sub.2 O.sub.2 Dependent Inhibition of Proteoglycan Biosynthesis, Baker, et al., The Journal of Rheumatology, 15(4):670-677, 1988.
Antioxidants Inhibit Proliferation and Cell Surface Expression of Receptors for Interleukin-2 and Transferrin in T Lymphocytes Stimulated with Phorbol Myristate Acetate and Ionomycin Chaudhri, et al., Cellular Immunology, 115:204-213, 1988.
Role of Flavonoids in the Oxygen-Free Radical Modulation of the Immune Response, Pignol, et al., Plant Flavonoids in Biology & Medicine II: Biochemical, Cellular . . . , 173-182, 1988.
Flavone-8-Acetic Acid Augments Systemic Natural Killer Cell Activity and Synergizes with IL-2 for Treatment of Murine Renal Cancer, Wiltrout, et al., The Journal of Immunology, 140(9):3261-3265, May 1, 1988.
Interleukin-2: Inception, Impact, and Implications, Smith, Kendall A., Science, 240:1169-1176, May 27, 1988.
Enhancement of Natural Killer Activity in Human Peripheral Blood by Flavone Acetic Acid, Urba, et al., The Journal of the National Cancer Institute, 80(7):521-525, Jun. 1, 1988.
The Development of New Immunotherapies for the Treatment of Cancer Using Interleukin-2, Rosenberg, Annals of Surgery, 208(1):121-135, Aug. 1988.
Interleukin 2 as a Pharmacologic Reagent, Lotze, eds., National Institutes of Health, Smith, Chapter 12, pp. 237-245, Oct. 28, 1988.
Augmentation of Natural Killer Activity, Induction of IFN and Development Tumor Immunity Du
Gehlsen Kurt R.
Hellstrand Kristoffer
Hermodsson Svante
MacMillan Keith D.
Maxim Pharmaceuticals, Inc.
LandOfFree
Elevation of circulating blood histamine levels does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Elevation of circulating blood histamine levels, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Elevation of circulating blood histamine levels will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2213998